Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Cisapride

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Cisapride
Clinical data
Trade namesPrepulsid, Propulsid
AHFS/Drugs.comFDA Professional Drug Information
MedlinePlusa694006
Pregnancy
category
Routes of
administration
By mouth (tablets), suspension
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability30-40%
Protein binding97.5%
MetabolismliverCYP3A4, intestinal
Eliminationhalf-life10 hours
Excretionkidney, bile duct
Identifiers
  • (±)-cis-4-amino-5-chloro-N-(1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl)-2-methoxybenzamide
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.072.423Edit this at Wikidata
Chemical and physical data
FormulaC23H29ClFN3O4
Molar mass465.95 g·mol−1
3D model (JSmol)
  • Clc1cc(c(OC)cc1N)C(=O)NC3CCN(CCCOc2ccc(F)cc2)CC3OC
  • InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29) checkY
  • Key:DCSUBABJRXZOMT-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cisapride is agastroprokinetic agent, adrug that increasesmotility in the uppergastrointestinal tract. It acts directly as aserotonin5-HT4 receptoragonist and indirectly as aparasympathomimetic. Stimulation of the serotonin receptors increasesacetylcholine release in theenteric nervous system. It has been sold under the trade namesPrepulsid (Janssen-Ortho) andPropulsid (in the United States). It was discovered byJanssen Pharmaceuticals in 1980. In many countries, it has been either withdrawn from the market or had its indications limited due to incidence of serious cardiac side-effects.[2] Propulsid was linked to children's deaths.[3]

The commercial preparations of this drug are theracemic mixture of bothenantiomers of the compound. The (+) enantiomer itself has the major pharmacologic effects and does not induce many of the detrimental side-effects of the mixture.[4]

Medical uses

[edit]

Cisapride has been used for the treatment ofgastroesophageal reflux disease (GERD). There is no evidence it is effective for this use in children.[5] It also increases gastric emptying in people with diabeticgastroparesis. Evidence for its use inconstipation is not clear.[6]

In many countries, it has been either withdrawn or had its indications limited because of reports of the side-effectlong QT syndrome, which may causearrhythmias. TheU.S. Food and Drug Administration (FDA) issued a warning letter to doctors,[7] and cisapride was voluntarily removed from the U.S. market on July 14, 2000. Its use in Europe has also been limited.[5] It was banned in India and in the Philippines in 2011.[8]

Veterinary uses

[edit]

Cisapride is still available in the United States and Canada for use in animals, and is commonly prescribed by veterinarians to treatmegacolon in cats.

Cisapride is also commonly used to treat GI stasis in rabbits, sometimes in conjunction withmetoclopramide (Reglan).

Kinetics

[edit]

Oralbioavailability of cisapride is approximately 33%. It is inactivated primarily by hepatic metabolism byCYP3A4 with a half-life of 10 hours. The dose of the drug should be reduced in case of liver diseases.[9]

Pharmacology and mechanism of action

[edit]

As aprokinetic agent that increasesgastrointestinal motility, cisapride acts as a selectiveserotonin agonist in the 5-HT4 receptor subtype. Cisapride also relieves constipation-like symptoms by indirectly stimulating the release ofacetylcholine, which acts onmuscarinic receptors.

See also

[edit]

References

[edit]
  1. ^Anvisa (2023-03-31)."RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União (published 2023-04-04).Archived from the original on 2023-08-03. Retrieved2023-08-16.
  2. ^"Propulsid To Go Off Market - Warning".MedicineNet. Retrieved2021-12-25.
  3. ^"PROPULSID: A Heartburn Drug, Now Linked to Children's Deaths".Los Angeles Times. 2000-12-20. Retrieved2021-12-25.
  4. ^US patent 5955478, Gray NM, Young JW, "Methods for treating gastrointestinal motility dysfunction using optically pre (+) cisapride", issued 1999-Sep-21 
  5. ^abMaclennan S, Augood C, Cash-Gibson L, Logan S, Gilbert RE (April 2010)."Cisapride treatment for gastro-oesophageal reflux in children"(PDF).The Cochrane Database of Systematic Reviews.2010 (4) CD002300.doi:10.1002/14651858.CD002300.pub2.PMC 7138252.PMID 20393933.
  6. ^Aboumarzouk OM, Agarwal T, Antakia R, Shariff U, Nelson RL (January 2011). "Cisapride for intestinal constipation".The Cochrane Database of Systematic Reviews (1) CD007780.doi:10.1002/14651858.CD007780.pub2.PMID 21249695.
  7. ^""Cardiac contraindications included in new FDA warnings about Propulsid"". medscape.com. January 25, 2000. Retrieved10 May 2021.
  8. ^"Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Archived fromthe original on 2015-02-21. Retrieved2013-09-17.
  9. ^Hedner T, Hedner J, Gelin-Friberg A, Huang ML, Van de Poel S, Woestenborghs R, Van Peer A, Heykants J (1990). "Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers".European Journal of Clinical Pharmacology.38 (6):629–31.doi:10.1007/bf00278595.PMID 2373139.S2CID 33641651.

Further reading

[edit]
  • Brenner GM (2000).Pharmacology. Philadelphia, PA: W.B. Saunders Company.ISBN 0-7216-7757-6.
  • Canadian Pharmacists Association (2000).Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom.ISBN 0-919115-76-4.
  • "Cisapride".Medline Plus. U.S. National Library of Medicine.

External links

[edit]
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium

compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(andPAMsTooltip positive allosteric modulators)
Antagonists
(andNAMsTooltip negative allosteric modulators)
Precursors
(andprodrugs)
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cisapride&oldid=1314337826"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp